Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial

被引:0
作者
Haixia Fu
Xueyan Sun
Ren Lin
Yu Wang
Li Xuan
Han Yao
Yuanyuan Zhang
Xiaodong Mo
Meng lv
Fengmei Zheng
Jun Kong
Fengrong Wang
Chenhua Yan
Tingting Han
Huan Chen
Yao Chen
Feifei Tang
Yuqian Sun
Yuhong Chen
Lanping Xu
Kaiyan Liu
Xi Zhang
Qifa Liu
Xiaojun Huang
Xiaohui Zhang
机构
[1] Peking University People’s Hospital,Collaborative Innovation Center of Haematology
[2] Peking University Institute of Haematology,Medical Center of Haematology, State Key Laboratory of Trauma, Burn and Combined Injury
[3] Peking University,Department of Haematology
[4] Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation,undefined
[5] National Clinical Research Center for Haematologic Disease,undefined
[6] Xinqiao Hospital,undefined
[7] Army Medical University,undefined
[8] Nanfang Hospital,undefined
[9] Southern Medical University,undefined
来源
BMC Medicine | / 22卷
关键词
Mesenchymal stromal cells; Haemopoietic stem cell transplantation; Haploidentical; Acute graft-versus-host disease; Steroid-refractory; Second-line therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 530 条
[1]  
Zeiser R(2017)Acute graft-versus-host disease - biologic process, prevention, and therapy N Engl J Med 377 2167-2179
[2]  
Blazar BR(2005)Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time Bone Marrow Transplant 36 757-769
[3]  
Gratwohl A(2021)Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the acute leukemia working party of the european society for blood and marrow transplantation J Hematol Oncol 14 53-1163
[4]  
Brand R(2012)First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation Biol Blood Marrow Transplant 18 1150-e167
[5]  
Frassoni F(2020)Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation Lancet Haematol 7 e157-378
[6]  
Rocha V(2013)Treatment and management of graft-versus-host disease: improving response and survival Ther Adv Hematol 4 366-1749
[7]  
Niederwieser D(2020)Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial Blood 135 1739-574
[8]  
Reusser P(2021)The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update J Hematol Oncol 14 145-748
[9]  
Einsele H(2005)Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease Br J Haematol 130 568-458
[10]  
Cordonnier C(2009)Therapy with mycophenolate mofetil for refractory acute and chronic GVHD Bone Marrow Transplant 44 739-440